Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence clinical  in vitro  diagnostics for kidney disease, announces that it will release its preliminary results for the year ended 30 June 2019 on Tuesday, 3 September 2019.

Download  full announcement Intended appointment of an additional Non-Executive Director Renalytix AI plc (AIM: RENX), a developer of artificial intelligence clinical  in vitro  diagnostics for kidney disease, announces the expansion of its core investigator group for lead product  KidneyIntelX  ™

Download  full announcement For the purposes of DTR5.6.1R of the Transparency Directive, the Company notifies the market of the following: As of 31 July 2019, the Company’s issued and fully paid share capital consists of 59,416,134 ordinary shares with a nominal value of £0.0025 each (“Ordinary

Download  full announcement RenalytixAI Expands Leadership Team with Focus on Reimbursement ahead of roll-out of artificial intelligence clinical in vitro diagnostic KidneyIntelX  ™ RenalytixAI plc (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces

Company expands leadership team with focus on reimbursement for artificial intelligence clinical in vitro diagnostic, KidneyIntelX™ NEW YORK, July 29, 2019 /PRNewswire/ --  Renalytix AI plc  (LON: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces the

Download  full announcement Renalytix AI welcomes US Administration’s dedication to advancing American kidney health Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, welcomes the Executive Order signed by the President of the

Download  full announcement Data development plan review continues with FDA under Breakthrough Device Designation Process Performance meets or exceeds targets for identifying Rapid Kidney Function Decline in patients with Type 2 diabetes and existing chronic kidney disease .

Data development plan review continues with FDA under Breakthrough Device designation process; Performance meets or exceeds targets for identifying rapid kidney function decline in patients with Type 2 diabetes and existing chronic kidney disease NEW YORK, July 9, 2019 /PRNewswire/ --  Renalytix AI